{"id":"NCT04322539","sponsor":"Hutchison Medipharma Limited","briefTitle":"A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer","officialTitle":"A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-12","primaryCompletion":"2022-07-29","completion":"2024-04-24","firstPosted":"2020-03-26","resultsPosted":"2023-09-14","lastUpdate":"2025-04-04"},"enrollment":691,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Colorectal Cancer","Metastatic Colon Cancer"],"interventions":[{"type":"DRUG","name":"Fruquintinib","otherNames":["HMPL-013"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fruquintinib Plus Best Supportive Care (BSC) Group","type":"EXPERIMENTAL"},{"label":"Placebo Plus BSC Group","type":"PLACEBO_COMPARATOR"}],"summary":"This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From date of randomization to death from any cause (up to 22 months)","effectByArm":[{"arm":"Fruquintinib + BSC Group","deltaMin":7.4,"sd":null},{"arm":"Placebo + BSC Group","deltaMin":4.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< .001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":33},"locations":{"siteCount":153,"countries":["United States","Australia","Austria","Belgium","Czechia","Estonia","France","Germany","Hungary","Italy","Japan","Poland","Spain","United Kingdom"]},"refs":{"pmids":["40888992","39952149","37331369","33993740"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":173,"n":456},"commonTop":["Asthenia","Hypertension","Decreased appetite","Diarrhoea","Fatigue"]}}